Clinical significance and the difference between programmed death-1 ligand-1 and ligand-2 in patients with esophageal cancer

被引：0

作者：

Okadome, Kazuo ^{[1
]}

Baba, Yoshifumi ^{[1
]}

Yagi, Taisuke ^{[1
]}

Kiyozumi, Yuki ^{[1
]}

Eto, Kojiro ^{[1
]}

Hiyoshi, Yukiharu ^{[1
]}

Nagai, Yohei ^{[1
]}

Ishimoto, Takatsugu ^{[1
]}

Iwatsuki, Masaaki ^{[1
]}

Iwagami, Shiro ^{[1
]}

Miyamoto, Yuji ^{[1
]}

Yoshida, Naoya ^{[1
]}

Baba, Hideo ^{[1
]}

机构：

[1] Kumamoto Univ, Kumamoto, Japan

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-4123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4123

引用

页数：2

共 50 条

[1] Clinical Significance of Programmed Death-1 Ligand-2 in Esophageal Cancer: Comparison with Programmed Death-1 Ligand-1
Okadome, Kazuo
Baba, Yoshifumi
Yagi, Taisuke
Kiyozumi, Yuki
Eto, Kojiro
Hiyoshi, Yukiharu
Ishimoto, Takatsugu
Nagai, Yohei
Iwagami, Shiro
Miyamoto, Yuji
Yoshida, Naoya
Baba, Hideo
CANCER SCIENCE, 2018, 109 : 414 - 414
[2] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Ohigashi, Y
Sho, M
Yamada, Y
Tsurui, Y
Hamada, K
Ikeda, N
Mizuno, T
Yoriki, R
Kashizuka, H
Yane, K
Tsushima, F
Otsuki, N
Yagita, H
Azuma, M
Nakajima, Y
CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2947 - 2953
[3] Clinical significance and therapeutic potential of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
Grimm, M.
Gasser, M.
Koenigshausen, M.
Stein, C.
Lutz, J.
Krol, S.
Thiede, A.
Heemann, U.
Waaga-Gasser, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Clinical significance and therapeutic potential of programmed death 1 ligand-1 and programmed death-1 ligand-2 expression in human colorectal cancer
Grimm, M.
Gasser, M.
Koenigshausen, M.
Stein, C.
Lutz, J.
Krol, S.
Nichiporuk, E.
Thiede, A.
Heemann, U.
Waaga-Gasser, A. M.
ONKOLOGIE, 2008, 31 : 80 - 80
[5] Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations
Hoskins, Emily L.
Samorodnitsky, Eric
Wing, Michele R.
Reeser, Julie W.
Hopkins, Julia F.
Murugesan, Karthikeyan
Kuang, Zheng
Vella, Raven
Stein, Leah
Risch, Zachary
Yu, Lianbo
Adebola, Serifat
Paruchuri, Anoosha
Carpten, John
Chahoud, Jad
Edge, Stephen
Kolesar, Jill
McCarter, Martin
Nepple, Kenneth G.
Reilley, Matthew
Scaife, Courtney
Tripathi, Abhishek
Single, Nancy
Huang, Richard S. P.
Albacker, Lee A.
Roychowdhury, Sameek
JCO PRECISION ONCOLOGY, 2023, 7
[6] Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer
Zhang, Ying
Zhu, Weipei
Zhang, Xueguang
Qu, Qiuxia
Zhang, Liyuan
ONCOLOGY LETTERS, 2017, 14 (06) : 7225 - 7231
[7] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
Yu Wei-Bo
Rao Jian-Yu
慢性疾病与转化医学（英文）, 2019, 5 (03) : 170 - 177
[8] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
Kim, Ji-Hyun
Kim, Shinn-Young
Shin, Eun-Young
Jung, Ji-Han
Choi, Hyun-Joo
Jun, Kyong-Hwa
ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
[9] Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1
Hsu, Jun-Te
Hsu, Chih-Sin
Le, Puo-Hsien
Chen, Tse-Ching
Chou, Wen-Chi
Lin, Chun-Yen
Yeh, Ta-Sen
JOURNAL OF SURGICAL RESEARCH, 2017, 211 : 30 - 38
[10] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
Liu, Xiaojun
Yang, Zhongxia
Latchoumanin, Olivier
Qiao, Liang
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860

← 1 2 3 4 5 →